CRISPR Therapeutics AG - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by CRISPR Therapeutics AG on January 12, 2026. The filing details significant clinical and preclinical updates across the Company's portfolio of in vivo gene editing, CAR-T cell therapy, and regenerative medicine programs.
Key Financial Metrics
The filing text does not provide specific financial values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on operational and clinical milestones.
Material Changes and Clinical Updates
- In Vivo Gene Editing (LNP Platform):
- CTX310 (ANGPTL3): Advanced to Phase 1b trials following positive Phase 1 data showing deep, durable triglyceride and LDL reductions with a single IV infusion.
- CTX320 (LPA): Demonstrated up to 73% reduction in LPA during dose escalation.
- CTX321 (Next-gen LPA): Entered IND/CTA-enabling studies; features a guide RNA with approximately two-fold greater potency in preclinical testing.
- Preclinical Candidates: CTX460 (SERPINA1 for AATD) emerged from the SyNTase platform; CTX340 (AGT for hypertension) is in IND/CTA-enabling studies.
- Zugocabtagene Geleucel (zugo-cel):
- Autoimmune Disease: Phase 1 trials ongoing for SLE, SSc, inflammatory myositis, ITP, and wAIHA. Notable data includes an SLE patient maintaining drug-free remission through month 9 and a second patient achieving SLEDAI-2K score of 0 through month 2.
- Oncology: Phase 1/2 trial in B-cell malignancies ongoing. Established a collaboration with Eli Lilly to evaluate zugo-cel with pirtobrutinib in aggressive B-cell lymphomas.
- Regenerative Medicine (Diabetes):
- CTX211: Clinical data showed detectable C-peptide levels 12 months post-implantation.
- CTX213: Next-generation candidate with compelling preclinical efficacy is progressing toward clinical trials.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the advancement of clinical programs and the potential efficacy of new candidates. Management cautions that actual results may differ materially due to risks outlined in the Company's most recent Form 10-K. No specific financial guidance or quantitative outlook was provided in this document.
Investor Verification Checklist
- Verify the specific enrollment numbers and primary endpoints for the ongoing Phase 1b trial of CTX310.
- Confirm the timeline for the initiation of clinical trials for the next-generation candidate CTX213.
- Review the terms of the collaboration agreement with Eli Lilly regarding the combination of zugo-cel and pirtobrutinib.
- Monitor the long-term durability of the drug-free remission observed in the SLE patient treated with zugo-cel beyond month 9.
- Check the Company's most recent Form 10-K for detailed risk factors related to gene editing safety and regulatory approval timelines.